Follow-up care and assessment of comorbidities and complications in patients with primary aldosteronism : The clinical practice guideline of the Taiwan Society of aldosteronism
Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved..
Primary aldosteronism (PA) is the most common form of endocrine hypertension, characterized by excess aldosterone production that leads to an increased risk of cardiovascular events and target organ damage. Both adrenalectomy and medical treatment have shown efficacy in improving clinical outcomes and comorbidities associated with PA, including a specific subtype of PA with autonomous cortisol secretion (ACS). Understanding the comorbidities of PA and establishing appropriate follow-up protocols after treatment are crucial for physicians to enhance morbidity and mortality outcomes in patients with PA. Additionally, the screening for hypercortisolism prior to surgery is essential, as the prognosis of patients with coexisting PA and ACS differs from those with PA alone. In this review, we comprehensively summarize the comorbidities of PA, encompassing cardiovascular, renal, and metabolic complications. We also discuss various post-treatment outcomes and provide insights into the strategy for glucocorticoid replacement in patients with overt or subclinical hypercortisolism. This clinical practice guideline aims to equip medical professionals with up-to-date information on managing concurrent hypercortisolism, assessing treatment outcomes, and addressing comorbidities in patients with PA, thereby improving follow-up care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 Suppl 2 |
|---|---|
| Enthalten in: |
Journal of the Formosan Medical Association = Taiwan yi zhi - 123 Suppl 2(2024) vom: 24. März, Seite S141-S152 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Li-Hsin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4964P6T9RB |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfma.2023.08.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361185111 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361185111 | ||
| 003 | DE-627 | ||
| 005 | 20240312233159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jfma.2023.08.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM361185111 | ||
| 035 | |a (NLM)37620221 | ||
| 035 | |a (PII)S0929-6646(23)00324-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pan, Li-Hsin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Follow-up care and assessment of comorbidities and complications in patients with primary aldosteronism |b The clinical practice guideline of the Taiwan Society of aldosteronism |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Primary aldosteronism (PA) is the most common form of endocrine hypertension, characterized by excess aldosterone production that leads to an increased risk of cardiovascular events and target organ damage. Both adrenalectomy and medical treatment have shown efficacy in improving clinical outcomes and comorbidities associated with PA, including a specific subtype of PA with autonomous cortisol secretion (ACS). Understanding the comorbidities of PA and establishing appropriate follow-up protocols after treatment are crucial for physicians to enhance morbidity and mortality outcomes in patients with PA. Additionally, the screening for hypercortisolism prior to surgery is essential, as the prognosis of patients with coexisting PA and ACS differs from those with PA alone. In this review, we comprehensively summarize the comorbidities of PA, encompassing cardiovascular, renal, and metabolic complications. We also discuss various post-treatment outcomes and provide insights into the strategy for glucocorticoid replacement in patients with overt or subclinical hypercortisolism. This clinical practice guideline aims to equip medical professionals with up-to-date information on managing concurrent hypercortisolism, assessing treatment outcomes, and addressing comorbidities in patients with PA, thereby improving follow-up care | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Comorbidity | |
| 650 | 4 | |a Complication | |
| 650 | 4 | |a Follow-up care | |
| 650 | 4 | |a Glucocorticoid | |
| 650 | 4 | |a Hyperaldosteronism | |
| 650 | 7 | |a Aldosterone |2 NLM | |
| 650 | 7 | |a 4964P6T9RB |2 NLM | |
| 700 | 1 | |a Chen, Ying-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Chien-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Chih-Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, Chi-Shin |e verfasserin |4 aut | |
| 700 | 1 | |a Yen, I-Weng |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Chieh-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Liang-Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Formosan Medical Association = Taiwan yi zhi |d 1992 |g 123 Suppl 2(2024) vom: 24. März, Seite S141-S152 |w (DE-627)NLM012627941 |x 0929-6646 |7 nnns |
| 773 | 1 | 8 | |g volume:123 Suppl 2 |g year:2024 |g day:24 |g month:03 |g pages:S141-S152 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfma.2023.08.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 Suppl 2 |j 2024 |b 24 |c 03 |h S141-S152 | ||